Multiple Sclerosis Clinical Trials

A listing of Multiple Sclerosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 54 clinical trials
Investigation of the Effect of Branched Chain Amino Acids on Fat-Induced Insulin Resistance in Healthy Adults.

Elevations in plasma levels of branched chain amino acids (BCAAs, comprising leucine, valine, and isoleucine), a large component of protein, are strongly associated with insulin resistance and type 2 diabetes, but mechanisms for this relationship are unclear. This protocol will determine whether excess BCAAs worsen free fatty acid-induced insulin resistance. …

  • 0 views
  • 19 Feb, 2024
  • 1 location
UPCC 06419: Phase 1/2 Open Label Multi-center Dose-Escalation Study to Assess the Safety Tolerability and Pharmacokinetics of Orally Administered Fimepinostat (CUDC-907) a PI3K and HDAC Inhibitor in Subjects with Relapsed and/or Refractory Lymphoma

This is a Phase 1/2, open-label, multicenter dose-escalation and dose-expansion trial evaluating the safety and tolerability of fimepinostat administered orally to patients with R/R lymphoma.

  • 0 views
  • 19 Feb, 2024
  • 1 location
UPCC 02619: Adjuvant Nivolumab Or Ipilimumab + Nivolumab Determined By Pathological Response To A Single Dose Of Neoadjvuant Nivolumab

Subjects with Stage III resectable melanoma will receive adjuvant therapy, nivolumab or ipilimumab plus nivolumab, based on whether a pathologic complete response (CR) or near CR (less than 10% viable tumor cells) is achieved with one dose of nivolumab in the neoadjuvant setting followed by surgery.

  • 0 views
  • 19 Feb, 2024
  • 1 location
Strategic Management to Optimize Response to Cardiac Resynchronization Therapy

Increasing values of RV-LV were associated with an increased effect size. The cutoff value of 70 ms was chosen because it maximized the potential yield of screened patients while still preserving a clinically important effect size.

  • 0 views
  • 19 Feb, 2024
  • 1 location